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Abstract
Pharmaceutical companies are in quite a predicament. With the majority of the global disease burden resting
on the developing world and the vast majority of wealth residing in industrialized countries, these
corporations are caught in a constant struggle between the altruistic inclinations they are expected to espouse
and their responsibility to turn a profit. With the international community placing unprecedented emphasis
on the universal right to health, the pharmaceutical industry has become a central facet of humanitarian work.
In recent years, wealthy governments have funneled vast sums of money toward treating the world’s poor and
the United Nations has allocated four of its eight Millennium Development Goals to specifically address
health concerns. A passing glance at the issues most plaguing the world today will easily explain this new
focus: one billion people worldwide lack access to clean water, eleven million die every year from infectious
diseases, and the World Health Organization (WHO) now estimates the number of AIDS-related deaths to
exceed three million annually. These tragedies produce ripple effects that can be felt throughout the inflicted
nations and, because of our globalized society, throughout the world. We live amidst a global health crisis of
the highest degree - one that simply cannot be addressed without the active participation of the
pharmaceutical industry.
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 Pharmaceutical companies are in quite a predicament. With the majority of the 
global disease burden resting on the developing world and the vast majority of wealth 
residing in industrialized countries, these corporations are caught in a constant struggle 
between the altruistic inclinations they are expected to espouse and their responsibility to 
turn a profit. With the international community placing unprecedented emphasis on the 
universal right to health, the pharmaceutical industry has become a central facet of 
humanitarian work. In recent years, wealthy governments have funneled vast sums of 
money toward treating the world’s poor and the United Nations has allocated four of its 
eight Millennium Development Goals to specifically address health concerns.1 A passing 
glance at the issues most plaguing the world today will easily explain this new focus: one 
billion people worldwide lack access to clean water,2 eleven million die every year from 
infectious diseases,3 and the World Health Organization (WHO) now estimates the 
number of AIDS-related deaths to exceed three million annually.4 These tragedies 
produce ripple effects that can be felt throughout the inflicted nations and, because of our 
globalized society, throughout the world. We live amidst a global health crisis of the 
highest degree—one that simply cannot be addressed without the active participation of 
the pharmaceutical industry. 
  But what should we realistically expect from these seeming hybrids of humanitarian actors 
and corporate entrepreneurs? Certainly we can acknowledge that the products they market are 
unlike most other commodities. Lifesaving medicines clearly deserve different consideration 
than an MP3 player or state-of-the-art vacuum. Yet, trying to fulfill both a benevolent agenda 
                                                 
1 “About the MDGs: Basics.” Millennium Development Goals. The United Nations Development Program. 
12 Oct. 2005. <http://www.undp.org/mdg/basics.shtml> 
2Evans, Tony. “A human right to health?” Third World Quarterly. 23 (2002) 211. 
3 Bailey, Michael, Ruth Mayne and Mohga Smith. “Fatal Side Effects: Medicine Patents under the 
Microscope.” Oxfam Great Britain: London, 2001, 2  
4 Dawar, Sandrine. “Trade and Human Rights.” Diss. The Fletcher School, Tufts University, 2004, 24. 
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while maintaining sustainable profits is problematic. It has caused these corporations to adopt 
policies that, paradoxically, harm the developing world. This merely underlines the fact that 
pharmaceutical companies will act first on their commercial interests and not simply on 
humanitarian impulses. Albeit far from the ideal that many of us hope for, understanding this 
reality and garnering more appropriate expectations of these businesses is an essential part of 
making progress in the field global health and humanitarianism more broadly.  
Patent Protection in the Developing World 
 One of the most controversial issues facing the pharmaceutical industry today is 
that of patent protection on essential medicines.5 Patents are defined as “monopolies 
granted by the State for a specified length of time for the commercial exploitation of a 
scientific or technological invention,” the goal of which is ultimately to spur innovation.6 
The Pharmaceutical Research and Manufacturers of America (PhRMA), an organization 
that represents the nation’s leading pharmaceutical companies, argues that such patents 
“protect their huge investments in researching and developing new drugs,” without which 
they would be unable to “recoup their costs and reinvest in other research projects.”7 
These R&D costs can add up to hundreds of millions of dollars to produce a single new 
drug, thus giving pharmaceutical companies a strong stake in seeing their patents 
protected across the globe. 8 Conveniently for them, the pharmaceutical lobby is an 
powerful force in Washington. These pharmaceutical corporations have great resources at 
                                                 
5 Tarullo, Daniel. “WTO, Developing Countries, and Regionalism.” American Enterprise Institute, 
Washington. 3 Oct. 2006. 
6 Bailey, Michael, Ruth Mayne and Mohga Smith. “Fatal Side Effects: Medicine Patents under the 
Microscope.” Oxfam Great Britain: London, 2001, 9.  
7 “Intellectual Property.” PhRMA. 20 Dec. 2006. 
<http://www.phrma.org/index.php?option=com_content&task=view&id=123&Itemid=109&cat=Intellectua
l+Property>  
8 Grabowski, Henry. “Patents, and New Product Development in the Pharmaceutical and Biotechnology 
Industries.” July 2002. Duke University.  25 Sept. 2006, 4.  
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their disposal and they know how to use them effectively. GlaxoSmithKline alone brings 
in $27.2 billion dollars a year, giving it significant pull amongst policymakers.9  In 2001, 
the pharmaceutical industry had 625 registered lobbyists in DC and a combined lobbying 
and campaign budget of $197 million from 1999-2000. 10 Pfizer’s marketing department 
alone is larger than the entirety of the World Health Organization.11 With an industry 
holding such wealth and power, one would correctly expect policies to be shaped to its 
benefit. 
 The inclusion of intellectual property in the World Trade Organization’s agenda is 
directly traceable to the efforts of two powerful U.S. companies, one of which was 
Pfizer.12 With great pressure from the pharmaceutical lobby, the United States backed the 
signing of the Agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS). The agreement established a minimum standard for patent protection that was 
to be reflected in the domestic laws of all WTO members. In terms of medicinal patents, 
the TRIPS Agreement allows inventors to hold the sole rights to the product or process 
for a minimum of twenty years—a coup for the U.S. pharmaceutical industry. 
Economists estimated that the implementation of the “TRIPS agreement was… expected 
to bring between $2.1 and $14.4 billion in additional profits to pharmaceutical companies 
in developed countries.”13 While the benefits of the agreement for these corporations are 
clear, the repercussions on the developing world are starkly different.  
 Basic economic principles dictate that creating a monopoly for a product allows 
the corporation to charge a higher price seeing as there are no cheaper alternatives 
                                                 
9 Bailey, 12. 
10 Dawar, 17.  
11 Thomas, Caroline. “Trade policy and the politics of access to drugs.” Third World Quarterly. 23 (2002): 257.  
12 Heywood, Mark. “Drug access, patents and global health: ‘chaffed and waxed sufficient.” Third World 
Quarterly. 23 (2002): 224. 
13 Dawar, 18.  
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available. The “rule-of-fives” theory for drug prices “indicates that the lowest prices 
generally are achieved only when there are five therapeutic alternatives or five competing 
producers.”14 The difference in price between the original, patented drug and the generic 
versions is enormous. For a hundred units of Ciprofloxacin, a drug that treats multi-
resistant tuberculosis, Bayer will charge somewhere between $169 and $549. The generic 
version from India is sold for $10.15 Even when drug companies reduce their prices in 
impoverished countries, the generic versions are still significantly cheaper. A 
combination of AZT and 3TC, both used to treat HIV/AIDS, is sold for $18 a day in the 
United States. GlaxoSmithKline reduces that price to $7 a day in Uganda. Still, the same 
drug, produced in Brazil, is marketed for a mere $1.50.16 This price disparity translates to 
the difference between life and death for millions of people.  
 While an undoubtedly complicated issue, the reality is that many of these essential 
drugs are simply too expensive for the majority of the developing world. Per capita health 
expenditures amount to barely $3 in Burundi and only $5 in Nepal.17 A total of 61 
countries have public drug expenditures of less than $10 per capita.18 Compare that to the 
several thousand dollars that one-year’s worth of tri-therapy HIV medicine can cost. 
Households, burdened by a poverty that is only intensified by disease, are even less likely 
to be able to pay for more expensive drugs. Because of the low government expenditures 
on health care in developing countries, poor citizens are already forced to take on a much 
larger proportion of these costs personally. For example, 85% of healthcare costs in India 
                                                 
14 “More Equitable Pricing for Essential Drugs: What Do We Mean and What Are the Issues?” The World 
Health Organization. Geneva: WHO, 2001. 16 Oct. 2006, 17.  
15 Bailey, 17.  
16 Ibid.  
17 Dawar, 25.  
18 Bailey, 5.  
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come out of the patients’ own pockets.19 Oxfam International conducted a survey that 
showed three-quarters of poor urban households in Kampala, Uganda cut spending on 
food to pay for medicine.20 This problem is enormous, and though not solving it entirely, 
generic manufacturers do provide essential medicines to demographics that are widely 
excluded by the high prices of Western drug makers.  
 At the 2001 Doha ministerial meeting, after great controversy over the original 
TRIPS Agreement and its effect on developing nations, WTO members signed the 
Declaration on the TRIPS Agreement and Public Health. It stated that the TRIPS 
Agreement “should not prevent Members from taking measures to protect public 
health…[and] to promote access to medicines for all.”21 The TRIPS Agreement allows 
governments to refuse “to issue a patent for an invention if its commercial exploitation is 
prohibited for reasons of public order or morality.”22 These added flexibilities are a 
significant step toward allowing countries to address urgent national emergencies. 
However, the pharmaceutical industry continues to heavily lobby the U.S. government, 
which, in turn, simply seeks the more stringent patent protection in its bilateral trade 
agreements while threatening sanctions on developing countries who refuse to enforce 
these intellectual property laws. The issue of access to essential medicines in poor nations 
is incredibly complex and the product of many factors—extreme poverty, corruption, and 
poor infrastructure to name a few. However, high prices spawned from monopolistic 
patent policies are one important facet of the issue. As long as pharmaceutical 
                                                 
19 More, 9.  
20 Bailey, 14.  
21  “Intellectual Property: Protection and Enforcement.” WTO.org. The World Trade Organization. 14 Oct. 
2006. <http://www.wto.org/english/thewto_e/whatis_e/tif_e/agrm7_e.htm> 
22 Ibid.  
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corporations continue to endorse and fight for these policies, they will effectively negate 
much of the good work they currently do in the developing world.  
Slanted Research and Development 
 When trying to assess the priorities of Western pharmaceutical companies, it is 
wise to first survey the medicines they have developed over the years. A cursory look 
will show a notable dearth in research for the diseases that primarily target poor 
populations. Only “ten percent of health research targets the illnesses that make up 90 
percent of the global disease burden. A miserly 0.2 percent of research efforts are 
directed to diarrhea, pneumonia and TB, which cause 18 percent of all illness.”23 Less 
than 0.5 of global drug development is directed to malaria research.24 Only eight of the 
1,233 drugs licensed by the U.S. Food and Drug Administration from 1975 to 1997 were 
developed specifically for tropical diseases in humans.25 PhRMA argues that global 
patent protection is necessary to promote future R&D, but it is overtly clear that this 
future R&D is unlikely to reflect the diseases that plague the populations that most need 
cheaper, generic drugs in the first place.  
 It is entirely logical for pharmaceutical companies to devote a relatively small 
percent of their resources to developing treatments for “poor people diseases.” Were 
they to discover an effective new drug, there would still be no market for the medicine 
despite the millions it could save. The populations that most need these drugs simply 
cannot afford to pay the prices that would produce a viable incentive to incur steep 
R&D costs. Even for diseases that affect the wealthy and impoverished alike, it is not 
                                                 
23 Bailey, 5. 
24 Lanjouw, Jean. “Drug Patents: Taking the Poorest Out of the Fight.” 28 Dec. 2003. ARE Department, 
U.C. Berkeley. 17 Oct. 2006 <http://are.berkeley.edu/~lanjouw/milken.pdf 
25 Ibid.  
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the poor that are enticing pharmaceutical corporations to develop new treatments. For 
instance, countries with a cumulative fifty-percent of the world’s population “contribute 
less than two percent to spending on cardiovascular drugs.”26 As our world becomes 
increasingly smaller and integrated through globalization, large multinational 
corporations such as Merck and Roche are forced to reevaluate the way they do 
business and direct their resources. Their products are introduced into previously 
untapped markets, but is that really enough to alter the allocation of funds for research 
and development? As of now, it appears as though pure market forces are overriding 
humanitarian impulses.  
Refocusing Responsibility 
 When allocating blame for issues as complex as a global health crisis, billion 
dollar corporations make for easy targets. Recent Hollywood productions, like The 
Constant Gardner, depict the pharmaceutical industry as willing to sacrifice anything in 
order to reap a profit. But is focusing so much critical attention on the practices of 
pharmaceutical companies really productive? Certainly their role in developing life-
saving drugs places them in a separate category that deserves careful scrutiny, but are our 
expectations of these companies unrealistic or even unfair? Pharmaceutical corporations 
survive off commercial success and, like any business, they will logically promote 
policies that can help foster this success. In this case, that may equate to supporting strict 
patent protection in developing countries or aligning R&D to target more profitable drugs 
like Prozac or Viagra. When looked at through this paradigm, the question is not why 
pharmaceutical companies do not support more humanitarian work. Instead, we must ask 
ourselves, what motivates them to do any at all?  The cynic might argue that it provides 
                                                 
26 Lanjouw  
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an agreeable public image for marketing purposes. While this is certainly true, I would 
argue that it also signals the industry’s acknowledgment of its critical role in battling the 
global health crisis and its inherent humanitarian obligations. 
 I, by no means, hope to excuse pharmaceutical corporations, or any corporations 
for that matter, from social and ethical accountability. As an undeniable force that 
permeates health, politics and development, they should be openly chastised when they 
endorse harmful policies or partake in ethically hazy practices. I only fear that placing so 
much attention and responsibility on this industry will result in little progress besides 
assigning an effective scapegoat. If we accept that pharmaceutical companies will act 
first and foremost in the interest of their businesses, then we can move on to develop new 
strategies to curb the possible ramifications this will have on treating the world’s poor. 
For example, if the pharmaceutical lobby will fight for patents on essential medicines in 
developing countries, how can we keep this influence from denying affordable medicine 
to the millions dying of treatable disease? The WTO’s changes to the TRIPS Agreement 
to better account for public health concerns prove that nations can, in fact, come together 
to seek a fairer solution. Yes, the pharmaceutical industry is powerful, but it is ultimately 
the United States government that is responsible for enacting policies that demand this 
strict patent protection. When addressing the issue of affordable drugs, we must look to 
the state and our nation’s leaders to act justly and promote health throughout the globe, 
even if it means denying the pharmaceutical lobby.  
 While pharmaceutical companies will most likely continue to focus their R&D on 
profitable treatments, we must be creative in addressing the severe lack of research into 
diseases plaguing the poor. Wealthy governments should provide greater funds to 
specifically research infectious diseases and deadly epidemics such as HIV/AIDS and 
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tuberculosis. Perhaps a separate fund should be established to focus on these particular 
illnesses or such an entity could also be linked to an agency such as the World Health 
Organization. New actors following different models also show great promise in tackling 
these issues. One World Health, the first non-profit pharmaceutical company in the 
United States, seeks out drugs that have been “developed by industry that could be 
targeted at devastating illnesses in impoverished countries.”27 The pharmaceutical 
industry, in its early stages of research, finds a number of positive leads that could 
develop into potential drugs. However, these drugs are often shelved due to lack of 
commercial prospects. One World Health identifies these drug leads, secures the 
intellectual property, and then fully develops the drug, seeing it through the clinical trials 
and regulatory approval phases. Afterwards, it partners with a manufacturing company to 
cheaply produce the drug and later with national health ministries and NGOs to secure its 
distribution.28 Certainly, One World Health’s non-profit model has its own limitations 
and is unlikely to become the norm for pharmaceutical companies. However, it is a 
perfect example of why we must understand how the pharmaceutical industry operates so 
that other actors with different incentives can better harness its work for humanitarian 
purposes.  
 The dire reality of the global health situation has dragged pharmaceutical 
corporations into the humanitarian realm and forced us to reevaluate our view of the 
industry. In a globalized society where the troubles of one region can so easily affect the 
populations of another, the health crises of the developing world are truly disastrous for 
                                                 
27 Corcoran, Elizabeth. “The Irony of Large Numbers.” Forbes. 9 Oct. 2006. 
<http://www.forbes.com/technology/2006/10/08/benetech-philanthropy-fruchterman-tech-
cz_ec_1009valleyletter.html> 
28 “Extraordinary Opportunities, Inspired Solutions.” Institute for One World Health. 31 Oct. 2006. 
<www.oneworldhealth.org> 
Robert Strain, University of Pennsylvania, 2007 PHF-Weiner Essay Prize, First Place 11
all. As the pioneers in medical innovation, pharmaceutical companies are not only faced 
with corporate responsibility but should also see themselves in terms of social 
responsibility. Unfortunately, however, we are confronted with the certainty that they will 
often fall short of the ethical standard with which we measure them. We must 
acknowledge the truth that these companies will and must operate first as businesses. 
While we should certainly encourage practices such as lowering prices in poor regions 
and sponsoring drug donation programs, but we must look to governments, multilateral 
institutions and other innovative non-governmental actors to pick up where the industry 
fails. 
  The actions of many pharmaceutical companies are seemingly paradoxical—
working to save lives in the developing world while perpetuating policies that harm these 
very countries. The contradiction becomes much more understandable after readjusting 
one’s expectations of these corporations as humanitarian actors. To assume that they 
should act purely benevolently is both naïve as well as counterproductive. To make any 
progress in battling the countless health crises that plague the world today, we must first 
acknowledge the actors involved, understand the roles they can reasonably play, and then 
focus on how they must interact with each other to best address some of the gravest 
threats facing society. This alone is not the grand solution that so many seek, but it is an 
essential beginning to one. A better, more realistic understanding of the pharmaceutical 
industry may, in fact, prove to be the most essential medicine of all. 
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